Shire (pharmaceutical company)
Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.
| Company type | Subsidiary |
|---|---|
| Nasdaq: SHPG | |
| ISIN | JE00B2QKY057 |
| Industry | Pharmaceuticals |
| Predecessor | Shire Pharmaceuticals Group Plc |
| Founded | 1986 |
| Defunct | 2019 |
| Fate | Acquired by Takeda |
| Headquarters | Massachusetts, United States |
Key people | Flemming Ornskov (CEO) Thomas Dittrich (CFO) |
| Revenue | $15,160.6 million (2017) |
| $2,455.2 million (2017) | |
| $4,271.5 million (2017) | |
Number of employees | 23,044 (2018) |
| Parent | Takeda Pharmaceutical Company (2019) |
| Website | www.shire.com |
Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products were available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices are located in Dublin, Ireland, the United States in Cambridge, Massachusetts, and Chicago, Illinois, and in Zug, Switzerland. In addition, Shire owns manufacturing sites in Lexington, Massachusetts, and Social Circle, Georgia. Shire's headquarters in Lexington, Massachusetts, will be integrated with Takeda's new U.S. headquarters, which is being relocated from Deerfield, Illinois, to the Boston area.